fedratinib and Liver-Cirrhosis

fedratinib has been researched along with Liver-Cirrhosis* in 1 studies

Other Studies

1 other study(ies) available for fedratinib and Liver-Cirrhosis

Article	Year
TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:8 Hepatic fibrosis, characterized by an excessive extracellular matrix (ECM) accumulation, leading to scar-tissue formation is a growing health problem worldwide. Hepatocellular damage due to liver injury triggers inflammation and transdifferentiation of quiescent hepatic stellate cells (HSCs) into proliferative, contractile, and ECM-producing myofibroblasts. Involvement of the Janus kinase (JAK)-2 pathway in the pathogenesis of fibrosis has been reported earlier. However, in this study, we have investigated the effect of selective JAK2 antagonist TG101348 in fibroblasts and inflammatory macrophages and Topics: 3T3 Cells; Animals; Carbon Tetrachloride; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hep G2 Cells; Humans; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Nitrogen Oxides; Pyrrolidines; Signal Transduction; Sulfonamides; Transforming Growth Factor beta	2019

Article

Year

TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:8

Hepatic fibrosis, characterized by an excessive extracellular matrix (ECM) accumulation, leading to scar-tissue formation is a growing health problem worldwide. Hepatocellular damage due to liver injury triggers inflammation and transdifferentiation of quiescent hepatic stellate cells (HSCs) into proliferative, contractile, and ECM-producing myofibroblasts. Involvement of the Janus kinase (JAK)-2 pathway in the pathogenesis of fibrosis has been reported earlier. However, in this study, we have investigated the effect of selective JAK2 antagonist TG101348 in fibroblasts and inflammatory macrophages and

Topics: 3T3 Cells; Animals; Carbon Tetrachloride; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hep G2 Cells; Humans; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Nitrogen Oxides; Pyrrolidines; Signal Transduction; Sulfonamides; Transforming Growth Factor beta

2019